검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Clarithromycin |
Overview Company | Karyopharm Therapeutics Inc |
Overview Modality | ADC |
Overview Target | Multiple Myeloma |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | EGFR proteins compared to infected untreated controls Higher total Nrf2 protein expression |
PK/PD Half-life | 3 h |
PK/PD Species | Mouse, with an IC 50 of 0. |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, with an IC 50 of 0. |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Enhancing 3-O-methylfunicone production by endophytic Talaromyces pinophilus J6 through culture optimization and its anti-Helicobacter pylori activity.. Endophytic fungi can produce metabolites with potential pharmaceutical applications through biosynthetic pathways strongly influenced by culture conditions. In this study, growth parameters (media composition and cultivation time) were systematica… |
Clinical Primary efficacy | ORR 6% |
Clinical ORR | 6% |
Clinical Result source | ClinicalTrials.gov NCT04302324 |
Clinical Data Tier / Score | A · 36 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Clarithromycin |
Overview Company | Karyopharm Therapeutics Inc |
Overview Modality | ADC |
Overview Target | Multiple Myeloma |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | EGFR proteins compared to infected untreated controls Higher total Nrf2 protein expression |
PK/PD Half-life | 3 h |
PK/PD Species | Mouse, with an IC 50 of 0. |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, with an IC 50 of 0. |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Enhancing 3-O-methylfunicone production by endophytic Talaromyces pinophilus J6 through culture optimization and its anti-Helicobacter pylori activity.. Endophytic fungi can produce metabolites with potential pharmaceutical applications through biosynthetic pathways strongly influenced by culture conditions. In this study, growth parameters (media composition and cultivation time) were systematica… |
Clinical Primary efficacy | ORR 6% |
Clinical ORR | 6% |
Clinical Result source | ClinicalTrials.gov NCT04302324 |
Clinical Data Tier / Score | A · 36 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교